

MARKED UP VERSION OF THE CLAIMS:

6. The agonist anti-CD40 molecule[s] of any one of claims [claim]1, 2, 3 or 4 which completely inhibits CD40L binding to CD40.
7. A composition comprising a combination of [agonist anti-CD40 molecules according to any of claims 1 to 5] at least one of the following:
 - a) An agonist anti-CD40 molecule that can bind to and stimulate professional or non-professional human APCs;
 - b) An agonist anti-CD40 molecule that enhances the stimulatory effect of CD40L on CD40 positive cells;
 - c) An agonist anti-CD40 molecule that induces phenotypical and functional maturation of monocyte derived dendritic cells;
 - d) An agonist anti-CD40 molecule that can simultaneously bind to CD40 with CD40L, as determined by their inability to inhibit CD40L binding to CD40 or their inability to inhibit of binding of sCD40 to CD40L.
9. The agonist anti-CD40 molecules of any one of claims 1 to [6] which are monoclonal antibodies.